In the last trading session, 1.72 million Arcutis Biotherapeutics Inc (NASDAQ:ARQT) shares changed hands as the company’s beta touched 1.24. With the company’s per share price at $10.25 changed hands at -$0.59 or -5.44% during last session, the market valuation stood at $1.20B. ARQT’s last price was a discount, traded about -28.49% off its 52-week high of $13.17. The share price had its 52-week low at $1.76, which suggests the last value was 82.83% up since then. When we look at Arcutis Biotherapeutics Inc’s average trading volume, we note the 10-day average is 2.68 million shares, with the 3-month average coming to 2.13 million.
Analysts gave the Arcutis Biotherapeutics Inc (ARQT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 1 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ARQT as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Arcutis Biotherapeutics Inc’s EPS for the current quarter is expected to be -0.28.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) trade information
Instantly ARQT was in red as seen at the end of in last trading. With action 10.22%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 217.34%, with the 5-day performance at 10.22% in the green. However, in the 30-day time frame, Arcutis Biotherapeutics Inc (NASDAQ:ARQT) is 5.24% up. Looking at the short shares, we see there were 28.06 million shares sold at short interest cover period of 14.47 days.
The consensus price target for the stock as assigned by Wall Street analysts is 27.5, meaning bulls need an upside of 62.73% from its current market value. According to analyst projections, ARQT’s forecast low is 18 with 51 as the target high. To hit the forecast high, the stock’s price needs a -397.56% plunge from its current level, while the stock would need to soar -75.61% for it to hit the projected low.
Arcutis Biotherapeutics Inc (ARQT) estimates and forecasts
Data shows that the Arcutis Biotherapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 26.08% over the past 6 months, a 63.76% in annual growth rate that is considerably higher than the industry average of 17.10%. Year-over-year growth is forecast to reach 202.30% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 54.69M. 2 analysts are of the opinion that Arcutis Biotherapeutics Inc’s revenue for the current quarter will be 56.26M. The company’s revenue for the corresponding quarters a year ago was 13.53M and 49.57M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 304.30%. The estimates for the next quarter sales put growth at 13.50%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -48.07%. The 2024 estimates are for Arcutis Biotherapeutics Inc earnings to increase by 64.44%, but the outlook for the next 5-year period is at 9.80% per year.
ARQT Dividends
Arcutis Biotherapeutics Inc is expected to release its next quarterly earnings report in December.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.15% of Arcutis Biotherapeutics Inc shares while 111.89% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 114.35%. There are 111.89% institutions holding the Arcutis Biotherapeutics Inc stock share, with JENNISON ASSOCIATES LLC the top institutional holder. As of 2024-06-30, the company held 9.3712% of the shares, roughly 11.57 million ARQT shares worth $107.62 million.
SUVRETTA CAPITAL MANAGEMENT, LLC holds the second largest percentage of outstanding shares, with 8.1021% or 10.0 million shares worth $93.04 million as of 2024-06-30.
